Chinook veterans join Jade
Plus: Apnimed hires Ramzi Benamar as CFO and an update from PhotonPharma
Jade Biosciences Inc. named Tom Frohlich CEO and a director and Hetal Kocinsky CMO; the autoimmune disease company also named Samsara BioCapital’s Eric Dobmeier chair of its newly formed board of directors. All three executives are veterans of Chinook Therapeutics Inc., where Frohlich was COO, Kocinsky was VP of translational medicine, and Dobmeier was CEO. Jade also topped off its August financing, raising a total of $95 million and adding Frazier Life Sciences and Versant Ventures to the syndicate. Also joining the board are Chris Cain and Tomas Kiselak of Fairmount, Lawrence Klein of Oruka Therapeutics Inc. (NASDAQ:ORKA), and Profound veteran Erin Lavelle.
Apnimed Inc. hired Ramzi Benamar as CFO and appointed Gary Sender to its board. Benamar and Sender were CFOs of Elucida Oncology Inc and Nabriva Therapeutics plc (NASDAQ:NBRV), respectively. The company’s Phase III study of AD109 to treat obstructive sleep apnea is expected to read out next year...